Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Nivolumab (Primary) ; Nivolumab
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Pharmacokinetics
Sponsors Taizhou Mabtech Pharmaceuticals

07 Apr 2024 Status changed from active, no longer recruiting to discontinued.
16 May 2023 Planned primary completion date changed from 24 Sep 2022 to 27 May 2024.
16 May 2023 Planned End Date changed from 24 Sep 2023 to 24 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com